NCT02269020 (RoboCurage ORL) is a Phase 1 clinical trial of Neck Dissection in Carcinoma, Squamous Cell, sponsored by Centre Hospitalier Universitaire de Nīmes.

Who is sponsoring NCT02269020?

NCT02269020 is sponsored by Centre Hospitalier Universitaire de Nīmes.

What drugs are being tested in NCT02269020?

Interventions in NCT02269020: Neck Dissection.

What condition does NCT02269020 study?

NCT02269020 studies Carcinoma, Squamous Cell.

Is NCT02269020 still recruiting?

NCT02269020 is currently completed. Last updated 11 January 2019.

Last reviewed 2019-01-11 · How we verify

NCT02269020: RoboCurage ORL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neck Dissection Via a Robot-assisted Transaxillary Approach in Patients With Squamous Cell Carcinoma of the Epi-larynx

Completed Phase 1 Last updated 11 January 2019

What this trial tests

Phase 1 trial testing Neck Dissection in Carcinoma, Squamous Cell in 3 participants. Completed in 14 September 2017.

Timeline

16 February 2015

Primary endpoint
4 September 2017

14 September 2017

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nīmes
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	16 February 2015
Primary completion	4 September 2017
Estimated completion	14 September 2017
Sites	1 location across France

Drugs / interventions tested

Neck Dissection

Conditions studied

Carcinoma, Squamous Cell — all drugs for Carcinoma, Squamous Cell →

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

Adults 18 to 89, any sex, with Carcinoma, Squamous Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main hypothesis of this study is that it is possible to make a unilateral selective dissection of ganglion levels IIa, III and IV using an endoscopic transaxillary approach via the da Vinci robotic system to reduce scarring, while respecting patient safety. Feasibility will be assessed by two combinded criteria: 1) performance of the surgical procedure respecting the different stages of visualization and dissection of key anatomical elements; 2) obtain a minimum of 9 lymph nodes when analyzing pathological evidence of the dissection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

[Robotic Surgery - Who is The Boss?]
Schuler PJ. · · 2018 · cited 6× · PMID 29905359 · DOI 10.1055/s-0043-121791

Verify or expand the search:

Other trials of Neck Dissection

Trials testing the same drug.

NCT04333537 — Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cance · Phase 2, PHASE3 · recruiting
NCT02784288 — Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk P · Phase 2 · completed

Other recruiting trials for Carcinoma, Squamous Cell

Currently open trials in the same condition.

NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
NCT06669572 — Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment · Phase 2 · recruiting
NCT06383728 — Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma · Phase 2 · recruiting
NCT04481256 — TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY · NA · recruiting
NCT04429542 — Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced · Phase 1 · recruiting

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

NCT07403474 — Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Ther · Phase 4 · not yet recruiting
NCT07455981 — Work Organization and Gambling Addiction · not yet recruiting
NCT07403500 — Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. · NA · not yet recruiting
NCT07342010 — Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT · Phase 4 · not yet recruiting
NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02269020 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nīmes
Last refreshed: 11 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02269020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing